iXCells Biotechnologies (“iXCells”) is a leading San Diego, California-based cell technology company focused on generating a wide variety of predictive human diseasemodels.
In addition, iXCells is pursuing custom and patient-specific services leveraging its expertise in the preparation, handling, engineering and differentiation of induced pluripotent stem cells (iPSCs) and in the isolation of primary cells along with associated services for descriptive and functional cell characterisation, compound screening and toxicology testing.
The company’s mission is to supply a diverse range of human disease models, derived from ethically sourced patient and healthy donor tissues, to support academic, pharmaceutical, and clinical researchers globally.
By providing predictive human cell models, ixCells aims to deepen the understanding of the molecular mechanisms underlying disease onset and progression as much as slow-down or reversion of disease, and accelerate the discovery and development of new medicines and innovative therapies to further advance precision medicine.
